Private biopharmaceuticals company pioneering the discovery of novel drugs using its expertise in Transient Receptor Protocols in ion channels and molecular regeneration

Sectors
Healthcare
Life Sciences
First Invested
2002
Early
Company Status
Acquired
Acquired by Eli Lilly and Company